Register to gain access to personalised information regarding Brand, the indications your are treating regularly, dosing guidelines and resources such as Major Studies, Patient Information and short videos curated to your special interest.

What are the Advantages of Xarelto^® for Protecting Your Patients with Comorbidities?

Stroke prevention in NVAF

Xarelto is indicated for stroke prevention in adults with non-valvular atrial fibrillation with one or more risk factors1

Stroke isn’t the only problem faced by people with NVAF and diabetes2–4^,18

How do you protect your patients like this?

Protection starts with getting to know your patient

Your patients deserve treatment that’s been thoroughly tested in patients like them

The pivotal clinical trial for Xarelto^® included the most patients with the highest HAS-BLED scores5-13

Life is the outcome that matters most in NVAF patients with diabetes

Take care of your patient’s future by lowering their risk of CV death5^,14

In the overall population in ROCKET AF, there was no significant difference in the outcome of cardiovascular death† or in the primary safety endpoint of major or non-major bleeding vs warfarin5
* RRR was calculated as 1-HR by Bayer

^† Reported as vascular death in publication, Bansilal S et al. 2015.14

Renal function: take care of what can’t always be replaced

Give the added benefit of better observed renal function preservation vs VKAs, even in patients with diabetes15^,16

Independent retrospective cohort analysis

Acknowleged by ACC/AHA/HRS for NVAF patients with renal impairment17

* After inverse probability of treatment weighting

Independent retrospective cohort analysis US database

Acknowleged by ACC/AHA/HRS for NVAF patients with renal impairment17

* RRR was calculated as 1-HR by Bayer.

^† After inverse probability of treatment weighting.

Protect your patients with the right dose, at the right time, for the right reason

Give your patients a treatment that meets their individual needs*^,1

* With caution in patients with CrCl 15–29 ml/min. Use is not recommended in patients with CrCl <15 ml/min.1
Xarelto 20 mg once daily: For patients with NVAF and CrCl ≥50 ml/min. Xarelto 15 mg once daily: For patients with NVAF and CrCl 15–49 ml/min.

AF, atrial fibrillation; ACC, American College of Cardiology; AHA, American Heart Association; AKI, acute kidney injury; ARR, absolute risk reduction; BMI, body mass index; CI, confidence interval; CrCl, creatinine clearance; CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESRD, end stage renal disease; HR, hazard ratio; HRS, Heart Rhythm Society; ICH, intracerebral haemorrhage; NVAF, non-valvular atrial fibrillation; OD, once daily; RRR, relative risk reduction; SE, systemic embolism; VKAs, vitamin K antagonists; YR, year.

HAS-BLED score is used to estimate major bleeding risk in patients with NVAF. CHADS₂-score is used to estimate stroke risk in patients with NVAF.

PP-XAR-ALL-1788-1

References

Xarelto (rivaroxaban) Summary of Product Characteristics. Xarelto (rivaroxaban) Summary of Product Characteristics. Return to content
Laakso M. Diabetes Care. 2010;33:442–449. Return to content
Molitch ME, et al. Diabetes Care. 2004;27:S79–S83. Return to content
Hemmelgarn BR, et al. Kidney Int. 2006;69:2155–2161. Return to content
Patel MR, et al. N Engl J Med. 2011;365:883–891. Return to content
Sherwood MW, et al. J Am Coll Cardiol. 2015;66:2271–2281. Sherwood MW, et al. J Am Coll Cardiol. 2015;66:2271–2281. Return to content
Connolly SJ, et al. N Engl J Med. 2009;361:1139–1151. Connolly SJ, et al. N Engl J Med. 2009;361:1139–1151. Return to content
Eikelboom JW, et al. J Am Coll Cardiol. 2013;62:900–908. Eikelboom JW, et al. J Am Coll Cardiol. 2013;62:900–908. Return to content
Granger CB, et al. N Engl J Med. 2011;365:981–992. Granger CB, et al. N Engl J Med. 2011;365:981–992. Return to content
Lopes RD, et al. Lancet. 2012;380:1749–1758. Lopes RD, et al. Lancet. 2012;380:1749–1758. Return to content
Center for Drug Evaluation and Research. FDA Briefing Information for the October 30, 2014 Meeting of the Cardiovascular and Renal Drugs Advisory Committee. Available at: https://wayback.archive-it.org/7993/20170405211223/https://www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM420704.pdf. [Accessed February 2020]. Center for Drug Evaluation and Research. FDA Briefing Information for the October 30, 2014 Meeting of the Cardiovascular and Renal Drugs Advisory Committee. Available at: https://wayback.archive-it.org/7993/20170405211223/https://www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM420704.pdf. [Accessed February 2020]. Return to content
Kato ET, et al. J Am Heart Assoc. 2016;5:pii:e003432. Kato ET, et al. J Am Heart Assoc. 2016;5:pii:e003432. Return to content
Giugliano RP, et al. N Engl J Med. 2013;369:2093–2104. Return to content
Bansilal S, et al. Am Heart J. 2015;170:675–682.e8. Bansilal S, et al. Am Heart J. 2015;170:675–682.e8. Return to content
Yao X, et al. J Am Coll Cardiol. 2017;70:2621–2632. Yao X, et al. J Am Coll Cardiol. 2017;70:2621–2632. Return to content
Bonnemeier H, et al. Comparative safety and effectiveness of non-bitamin K oal anticoagulatns vs phenprocoumon in patients with non-valvular atrial fibrillation and diabetes – results from the RELOADED Study. ESOC 2019, 22–24 May; Milan , Italy. Abstract AS25-069. https://journals.sagepub.com/doi/full/10.1177/2396987319845581 Bonnemeier H, et al. Comparative safety and effectiveness of non-bitamin K oal anticoagulatns vs phenprocoumon in patients with non-valvular atrial fibrillation and diabetes – results from the RELOADED Study. ESOC 2019, 22–24 May; Milan , Italy. Abstract AS25-069. https://journals.sagepub.com/doi/full/10.1177/2396987319845581 Return to content
January CT, et al. Circulation. 2019;140:e125–e121 Return to content
Echouffo-Tcheugui JB, Shrader P, Thomas L et al. J Am Coll Cardiol 2017;70:1325–1335. Return to content

RELATED PODCAST
CAD or symptomatic PAD discussion

RELATED VIDEOS
Coronary Artery Disease Causes and Consequences

DOSING GUIDE

PRACTICAL MANAGEMENT

PRESCRIBING INFORMATION

What are the Advantages of Xarelto^® for Protecting Your Patients with Comorbidities?

Stroke prevention in NVAF

Stroke isn’t the only problem faced by people with NVAF and diabetes2–4^,18

Your patients deserve treatment that’s been thoroughly tested in patients like them

Life is the outcome that matters most in NVAF patients with diabetes

Renal function: take care of what can’t always be replaced

Protect your patients with the right dose, at the right time, for the right reason

References

If you would prefer to visit your local website, please select your country:

DOSING GUIDE

PRACTICAL MANAGEMENT

PRESCRIBING INFORMATION

What are the Advantages of Xarelto® for Protecting Your Patients with Comorbidities?

Stroke prevention in NVAF

Stroke isn’t the only problem faced by people with NVAF and diabetes2–4,18

Your patients deserve treatment that’s been thoroughly tested in patients like them

Life is the outcome that matters most in NVAF patients with diabetes

Renal function: take care of what can’t always be replaced

Protect your patients with the right dose, at the right time, for the right reason

References

What are the Advantages of Xarelto^® for Protecting Your Patients with Comorbidities?

Stroke isn’t the only problem faced by people with NVAF and diabetes2–4^,18